Abstract
Type 2 diabetes mellitus (T2D) presents a major health and economic burden that could be alleviated with improved early prediction and intervention. While standard risk factors have shown good predictive performance, we show that the use of blood-based DNA methylation information leads to a significant improvement in the prediction of 10-year T2D incidence risk.
Previous studies have been largely constrained by linear assumptions, the use of CpGs one-at-a-time, and binary outcomes. We present a flexible approach (via an R package, MethylPipeR) based on a range of linear and tree-ensemble models that incorporate time-to-event data for prediction. Using the Generation Scotland cohort (training set ncases=374, ncontrols=9,461; test set ncases=252, ncontrols=4,526) our best-performing model (Area Under the Curve (AUC)=0.872, Precision Recall AUC (PRAUC)=0.302) showed notable improvement in 10-year onset prediction beyond standard risk factors (AUC=0.839, PRAUC=0.227). Replication was observed in the German-based KORA study (n=1,451, ncases = 142, p=1.6×10-5).
Competing Interest Statement
R.E.M has received a speaker fee from Illumina and is an advisor to the Epigenetic Clock Development Foundation. A.M.M has previously received speaker fees from Janssen and Illumina and research funding from The Sackler Trust. L.M has received payment from Illumina for presentations and consultancy. All other authors declare no competing interests.
Funding Statement
Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006) and is currently supported by the Wellcome Trust (216767/Z/19/Z). DNA methylation profiling of the Generation Scotland samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL; Reference 104036/Z/14/Z). The DNA methylation data assayed for Generation Scotland was partially funded by a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404; awardee: Dr David M Howard) and by a JMAS SIM fellowship from the Royal College of Physicians of Edinburgh (Awardee: Dr Heather C Whalley). D.A.G. is supported by funding from the Wellcome Trust 4–year PhD in Translational Neuroscience–training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. C.A.V. is a Chancellor's Fellow funded by the University of Edinburgh. D.L.Mc.C. and R.E.M. are supported by Alzheimer's Research UK major project grant ARUK–PG2017B–10. R.E.M. is supported by Alzheimer's Society major project grant AS–PG–19b–010. Recruitment to the CovidLife study was facilitated by SHARE— the Scottish Health Research Register and Biobank. SHARE is supported by NHS Research Scotland, the Universities of Scotland and the Chief Scientist Office of the Scottish Government. The KORA study was initiated and financed by the Helmholtz Zentrum Mü;nchen — German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research has been supported within the Munich Center of Health Sciences (MC–Health), Ludwig–Maximilians–Universität, as part of LMUinnovativ and is supported by the DZHK (German Centre for Cardiovascular Research). The KORA study is funded by the Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed–bayern.de).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021), providing generic ethical approval for a wide range of uses within medical research. The KORA studies were approved by the Ethics Committee of the Bavarian Medical Association (Bayerische Landesärztekammer; S4: #99186) and were conducted according to the principles expressed in the Declaration of Helsinki. All study participants gave their written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The study has been updated to focus more on survival models and also has a greatly increased sample size since the previous submission. Manuscript and supplementary files updated.
Data Availability
According to the terms of consent for Generation Scotland participants, access to data must be reviewed by the Generation Scotland Access Committee. Applications should be made to access@generationscotland.org. All code is available with open access at the following Gitlab repository: https://github.com/marioni-group MethylPipeR (version 1.0.0) is available at: https://github.com/marioni-group/MethylPipeR MethylPipeR-UI is available at: https://github.com/marioni-group/MethylPipeR-UI The informed consents given by KORA study participants do not cover data posting in public databases. However, data are available upon request from KORA Project Application Self-Service Tool (https://epi.helmholtz-muenchen.de/). Data requests can be submitted online and are subject to approval by the KORA Board.
